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Abstract 
Background: Peripartum cardiomyopathy (PPCM) is a rare type of cardiomyopathy of unknown aetiology 
associated with significant mortality and morbidity and characterized by heart failure in late pregnancy or 
puerperium. Diagnosis remains a challenge, as PPCM symptoms vary and may mimic those commonly experienced 
by women during pregnancy and postpartum. Objectives: to evaluate profile of peripartum cardiomyopathy in 
pregnant women and analyze their outcome on maternal cardiac status with six month follow up. Methods: In this 
retrospectively designed study all patients admitted with the diagnosis of acute severe PPCM at three service 
hospitals in the country located in central India, North-eastern and western region, meeting the inclusion criteria 
over a period of 7 years, were enrolled and followed up for 6 months post partum. The LVEF and Left ventricular 
end diastolic dimension (LVEDD) was assessed by echocardiography at baseline, 3 months and six month 
postpartum. Mortality and survival with normal or depressed ejection fraction were determined. Predictors of 
outcome were evaluated. Results: The presentation of the cases of in our setup was different and outcome was much 
better than most of the reported series. In our cases, in majority acute deterioration in unregistered cases in NYHA 
Class IV in multi-gravida was noted. In follow up for 6 months, there was only one mortality noted unrelated to 
cardiomyopathy. Conclusion: We conclude that our subset of PPCM cases had different risk factors such 
multiparity, advance age, poor socioeconomic status, hypertension and to colitis use as risk factors. New drugs were 
used prior to the pregnancy, such as pentoxyphyline, bromocriptine and cabergoline along with digoxin, diuretics 
and continuation of beta-blockers. Newer interventions such as plasmapheresis, immunoadsorption, ventricular 
assist devices and heart transplantation were not used. One mortality case was noted in 6 month follow up.  
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Introduction 
Congestive heart failure (CHF), occurring during the 
peripartum period, was first described in 1849.[1] 
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However, it was not until the 1930s when it was officially 
 recognized as a clinical entity occurring  as a 
consequence of pregnancy.[2]  In the 1970s, a 20-year 
experience following 27 patients who developed 
cardiomegaly in the puerperium was published, and the 
term peripartum cardiomyopathy (PPCM) was established 
by Demakis and Rahimtoola in 1971.[3] Since then, we 
have developed a greater understanding through data 
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collection and improved diagnostic methods resulting in 
PPCM becoming a well-defined form of Heart Failure.  
The clinical course varies between complete recovery to 
rapid progression to end stage heart failure and even 
death. Standard heart failure treatment, with 
adjustments for women who are pregnant or lactating, is 
the treatment of choice. Disease specific therapeutic 
strategies, including prolactin blockade, show promise. 
National and international registries and collaborative 
research efforts are warranted to characterize this 
disease better and to develop novel treatments that can 
improve outcomes.[4]  
Proposed etiologies and patho-physiological mechanisms of 
PPCM are inflammation, infection, abnormal immune 
response to pregnancy, abnormal response to haemodynamic 
stress of pregnancy, increased myocyte apoptosis, abnormal 
hormonal response, increased adrenergic tone, excessive 
prolactin production and genetics.[5] 
Today PPCM remains a rare yet significant cause of 
maternal morbidity and mortality. This was common in 
African population. Being a relatively rare entity, there are 
small sample studies only available.[6,7] The variety of 
risk factors describes by different authors have further 
confused the issue .In this study we have tried to analyze 
the cases of heart failure in peripartum period in weather 
registered or unregistered cases of primi as well as multi-
gravida. All singleton pregnancy which by chance with 
normal and presentation delivered as per available 
practices of assisted vaginal delivery or planned cesarean 
section. 
This study was conducted to evaluate profile of 
peripartum cardiomyopathy in pregnant women and 
analyze their outcome on maternal cardiac status with 
six month follow up. 
Material and Methods 
This retrospective study was conducted on 27 pregnant 
women in a tertiary care hospital of Central India, in 
June 2019 to June 2020. All consecutive PPCM patients 
admitted for management of acute heart failure were 
enrolled in the study. Ethical clearance was taken from 
the institutional review board. Being a retrospective 
study, written informed consent was not taken from the 
patient or their relatives. 
PPCM was defined as estimated LV ejection fraction of 
less than 45% with no other obvious cause of LV 
dysfunction in the last month of pregnancy or 5 months 
postpartum. 
PPCM patients admitted for management of heart 
failure of age more than 18 years were included in the 
study. Patients having past history of congenital heart 
disease with or without corrective surgery, valvular heart 
disease, coronary artery disease, severe sepsis, alcohol 
abuse, chemotherapy and any history of chest radiation 
were excluded from the study. 
Demographic, clinical and echocardiographic 
parameters were recorded at the time of enrollment. 
LVEF was calculated by eyeballing method. LVEDD 
was taken in parasternal long axis view. Clinical 
evaluation and echocardiography was done neat first 
contact in all patients, 3 months and 6 months in 
surviving patients.  
Complete recovery was defined as LVEF more than 
50% and recovery with depressed ejection fraction was 
defined as ejection fraction less than 50%.  
All patients received the guideline recommended 
standard medical treatment for heart failure wherever 
applicable. The primary end point was the 6-month 
outcome (mortality verses survival with normal or 
depressed ejection fraction).  
All the data was collected and transferred in MS excel 
format. Descriptive analysis with mean ± standard 
deviation (SD) was calculated for numerical variables. 
Frequencies with percentages were given for categorical 
variables. Chi square test was applied to find the 
significant correlation between the variables and 
outcome by using SPSS version 21. 
Results 
A total of 27 women were included in the study. Mean 
age of the study population was 29±5.6 years (range 20-
40).  Outcomes of the patients 25(92.5%) women were 
multi-gravida with a mean parity of 2.74±1.7. (Table -2) 
23 (86%) women had symptom onset in pre-partum 
period. Twenty two (95.65%) patient have undergone 
planned cesarean section within 48 hrs of reporting to 
the hospital under care of multidisciplinary medical 
team.  
One patient (4.3%) has undergone assisted vaginal 
delivery. 24 patients (88.88%) had pulmonary edema at 
the time of admission. All patients had singleton 
pregnancy incidentally. Mean duration of follow up was 
200 days (164-257days). All surviving women were 
followed up for more than 6 month as shown in Table1.  
Mean LVEF at study entry was 26.82 (15-39%). Sixty 
four percent (n-17) had LVEF less than 30 % at the 
study entry while 36% (n=10) had more than 30% 
LVEF.  
Patients with LVEF less than 30 % were followed up 
more frequently and an additional echocardiographic 
examination was done on completion of one month and 
ACE inhibitors/ARBs were optimized in postpartum 
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phase. Mean LVEF at 3-month follow up was 39.31% 
with the mean increment by 12.5. Mean LVEDD at 
study entry was 52.9 (44-70mm), which decreased by a 
mean of 4.3 mm during follow up as shown in Table 6. 
Of the 17 patients who had LVEF, 30% at the time of 
presentation and LVEDD also less than 60 mm as 
shown in  
During the 6-month follow up postpartum, 1 (3.7%) 
women died unrelated to CVS illness due to viper snake 
bite at 5th month post-partum. 17 (62.9%) women 
survived with full recovery and 9 (33.3%) were 
surviving with depressed ejection fraction, one patient 
died.  
Table 1: Clinical characteristics of the patients (N= 27) 
Parameter Values 
Mean age (years) 29±5.6 (20-40) 
Symptom onset before delivery 23 (86%) 
Symptom onset after delivery 4 (14%) 
Preterm delivery 0 
Term delivery 27 (100%) 
Pulmonary oedema at presentation 24 (88.88%) 
Vaginal delivery 02 (7.4%) 
LSCS 25 (92.59%) 
Primigravid 2 
Mean parity 2.74± 1.7(1-4) 
 
Table 2: Characteristics of patients with PPCM (n = 27) 
Age (Years) N % Mean 
20 – 30 
6 22 31.81 ± 3.7 
> 30 21 78 
Parity 
1 2 7.4 2.74 ± 1.7 
2 14 51.8 
3 and more 11 40.7 
Gestational Age At Diagnosis 
Antepartum 23 85  
Postpartum 04 15  
Functional Class At Diagnosis 
NYHA class    
I 0 0  
II 0 12.5  
III 23 85  
IV 4 15  
Body weight in Kg   71.91 ± 12.92 
Complications noted at presentation 
Chronic hypertension 2 7
.4 
 
Pre-eclampsia 1 3.7  
Long-term Tocolytic 2 7
.4 
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Table 3: Pregnancy outcome of patients with peripartum cardiomyopathy and fetal complications. (n = 
27) 
 Outcomes  N % 
Maternal Spontaneous Vaginal Delivery 2 7.4 
Assisted Vaginal Delivery 2 7.4 
Lower Segment Caesarian Section 23 85 
Cardiac  Complications Congestive heart failure 27 100 
Arrhythmias 8 29.6 
Thromboembolism   7.4 
ICU admission 27 100 
Recovery 27 100 
Death in follow up period  1 3.7 
Foetal   
 Alive 27 100 
Stillborn 0 0 
Neonatal Deaths 0 0 
Intra Uterine Growth Retardation 10 37.0 
NICU admission 24 88.88 
Table 4: Electrocardiographic features of Postpartum cardiomyopathy cases and mean serum BNP level 
Criteria Primigravid (02) Multigravida (25) 
No change 0 01 
Sinus tachycardia 2 23 
ST-T change biventricular 1 23 
ST-T changes only LV type 1 02 
T inversion 2 25 
Total 2 25 
BNP level  1762± 52 2354± 762 
Table 5: Ejection fraction according to sub groups Echocardiography at the presentation 
Ejection fraction Primi Multigravida 
<30 2 13 
31-34 0 10 
35-39 0 2 
>40 0 0 
Total 2 25 
Table 6. Echocardiographic parameters and myocardial recovery at 6 months 





LVEF at study entry, 30 %(17) 14 (82.35%) 3 (17.7) 0.67 
LVEF at study entry >30 %(10) 9 (90%) 1 (10%) 
Total 23 (85.1%) 4 (14.9%) 
 
Discussion  
In this retrospectively conducted on the preserved data 
study twenty-seven women with PPCM were enrolled 
and treated with standard heart failure medical 
management. 
The incidence of PPCM varies worldwide reported 
prevalence of PPCM in non African countries ranges 
between 1:3,000 - 1:15,000 live births.
4-7
 In our study 
done on collected data on a mobile  population done in 
very long  period of time, the incidence cannot be 
assessed. Common reported risk factors for PPCM are 
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advanced maternal age, multiparity, multiple gestation, 
black race, obesity, malnutrition, gestational 
hypertension, pre-eclampsia, poor antenatal care, 
alcohol and tobacco abuse, low socio economic 
conditions and long term to calyces as found in various 
studies.[8-10] In our study the most significant risk 
factors found were, advancing maternal age, 
multiparity, poor antenatal care and late presentation of 
six unregistered cases mean age of 31.18 years, chronic 
hypertension and pre-eclampsia and long term tocolysis. 
PPCM has been reported mostly in women older than 
30 years.[7-12] In our study also the mean age noted 
was 31.81 ± 3.7 years despite the trend of young age 
marriages in our society. Only one patient was a primi 
grand a with 23 being Para>3 which indicates 
multiparity as a major risk factor.7-12 In the USA 
majority of afflicted Americans are of African- 
American origin[13,14] though Asians, Hispanic and 
Caucasian mothers are also affected. The reason for the 
association of PPCM with higher age, parity, multiple 
gestation and black race is not fully understood. 
Pre-eclampsia and chronic hypertension have been 
associated with a significant number of PPCM cases in 
various studies.[11] Our study showed an association of 
15%. Similarly, long term tocolysis with oral 
salbutamol and terbutaline in women with preterm labor 
especially if combined with antenatal steroid 
administration for fetal lung maturation is a risk factor. 
Two patients with multiple pregnancy, received 
tocolysis combined with antenatal steroids and later 
developed life threatening cardiomyopathy in late third 
trimester.[12] Though all patients were in severe heart 
failure, all had clinical recovery. One of the patients 
died during the follow up of six months due non 
cardiovascular cause snake bite. This study is conducted 
in resourced state funded medical establishment, hence 
strict follow up and frequent Echocardiography was 
done to evaluate the progress of the recovery and 
optimization of therapy by multi disciplinary team. This 
result is superior to the findings of IPAC study, which 
had 13% major events at the end of one year.[15] 
Though PPCM resembles dilated cardiomyopathy 
(DCM) clinically LV may not always be dilated. The 
ejection fraction is nearly always reduced below 
45%.This study found a  mean ejection fraction of 26.82 
±8.38 (15-45%) similar to a study (28±9.9%) in 
USA.[16] All patients who  had LVEF less than 30% at 
baseline were followed up more persistently and 
frequent BNP level and Echocardiography was done 
antifaiIure therapy was optimized. LVEF >30 % was 
not associated with better LV recovery at 3 months (P 
value 0.67) as shown in Table 6. This finding is in 
contrary to the finding of IPAC study.[17] 
Early recovery in patients with PPCM is significantly 
related to the degree of myocardial insult at the time of 
diagnosis. Recovery of LV function was more in 
(54.5%) if the baseline LVEDD was less than 60 mm 
but this value was not statistically significant to 
correlate with the better outcome.[18] 
Although the disease has been reported in women 
between the ages of 16 and 44 years, the mean age of 
women with PPCM in the United States has ranged 
from 27 to 33 years.[19] 
Multiparty has been described as one of the 
predisposing factors in some studies from Pakistan 
(3.66±1.5and3.66±1.41, respectively)9,10 but majority 
of the women in the similar single centre study from 
Nepal done in short time period  study were primi  
gravida (64%) with mean parity of 1.68±0.56. 
PPCM can present both before and after delivery. In this 
study majority of women (88.8%) became symptomatic 
in antepartum period. The result is similar to other 
previous studies (71% in USA, and 68.8% in 
Pakistan).[8,19] 
All the patients required ICU admission; patients with 
LVEF less than 30% were exhibited with anticoagulant 
therapy in form of LMWH. Post partum reported cases 
were also exhibited with Pentoxyphylin therapy in doses 
400 mg TDS in three cases. Being very small subset of the 
study the therapeutic comparison was not done. 
Small number of the study population was a major 
limitation of the study also done in retrospect in a long 
period data. Patients were enrolled only if they were 
admitted with heart failure in hospital, thus the study 
doesn’t find out the outcome of less severe disease or if 
the therapy is initiated early in the course. 
Family-planning counselling is an important aspect of 
the care of patients after a diagnosis of PPCM. 
Subsequent pregnancy after a diagnosis of PPCM 
carries higher risk of relapse if left ventricular systolic 
function is not fully recovered first; and even with full 
recovery some additional risk of relapse remains. 
The reported incidence and prognosis varies according 
to geography and the disease is likely due to multiple 
factors. As this study included very few cases, a large 
number of patients required to give a significant result. 
Results may vary with geography, ethnicity, living 
standard, age, parity, associated or systemic disorders, 
habits and socioeconomic status.[20] Further 
investigation regarding the incidence, pathophysiology, 
genetics, treatment, and prognosis of patients with 
PPCM is warranted and would be greatly facilitated by 
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the establishment of national and international registries 
and collaborative research efforts.  
Conclusion 
This study demonstrated better survival outcome even 
in the patients with severe acute PPCM. PPCM is a 
heterogeneous disease that affects women during their 
last months of pregnancy or during their first months 
postpartum. Early diagnosis, frequent evaluation and 
proper management of heart failure can contribute in 
the positive outcomes. The higher maternal age and 
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